Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS malignancy consortium study 047 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • HIV Infections
  • HIV-1
  • Lymphoma, AIDS-Related
  • Neoplasm Recurrence, Local

abstract

  • Profound immunodeficiency and high HIV-1 viral load do not preclude attainment of complete response after DR-COP with highly active antiretroviral therapy. The regimen is tolerable, and use of rituximab was not associated with death as a result of infection during treatment. This approach may be useful in patients in whom the more intensive infusional regimens are impractical.

publication date

  • January 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3530691

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.42.4648

PubMed ID

  • 23169503

Additional Document Info

start page

  • 58

end page

  • 64

volume

  • 31

number

  • 1